CSIMarket
 
Akebia Therapeutics Inc   (AKBA)
Other Ticker:  
 
 
Price: $2.0000 $-0.21 -9.502%
Day's High: $2.221 Week Perf: 3.09 %
Day's Low: $ 1.91 30 Day Perf: 32.45 %
Volume (M): 10,251 52 Wk High: $ 2.33
Volume (M$): $ 20,501 52 Wk Avg: $1.20
Open: $2.20 52 Wk Low: $0.49



 Market Capitalization (Millions $) 371
 Shares Outstanding (Millions) 185
 Employees 384
 Revenues (TTM) (Millions $) 195
 Net Income (TTM) (Millions $) -52
 Cash Flow (TTM) (Millions $) -49
 Capital Exp. (TTM) (Millions $) 0

Akebia Therapeutics Inc
Akebia Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts, and has a subsidiary in Tokyo, Japan. Founded in 2007, Akebia's mission is to make a meaningful difference in the lives of patients with chronic kidney disease (CKD) by advancing the development of innovative therapies.

The company's lead compound is vadadustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor that is designed to mimic the body's natural response to hypoxia (low oxygen levels) by stimulating erythropoiesis (the production of red blood cells). Kidney disease patients often suffer from anemia, which is a shortage of red blood cells, and vadadustat is aimed at treating this condition in CKD patients.

In clinical trials, vadadustat has demonstrated efficacy and safety in increasing hemoglobin levels in both incident and prevalent CKD patients with anemia. Akebia is conducting Phase 3 trials to evaluate the long-term safety and efficacy of vadadustat compared to conventional therapy with erythropoiesis-stimulating agents (ESAs) for the treatment of anemia associated with CKD.

Aside from vadadustat, Akebia is also exploring other drug candidates for the treatment of kidney diseases. These include AKB-6899, a selective dopamine D1 receptor agonist, and AKB-5169, a selective HIF-2 alpha inhibitor.

Akebia has established partnerships with several pharmaceutical companies to develop and commercialize vadadustat in various regions around the world. Partnerships include Otsuka Pharmaceutical Co. Ltd. for Japan, Mitsubishi Tanabe Pharma Corporation for Asia, and Vifor Pharma Group for Europe, Middle East, and Africa.

Overall, Akebia Therapeutics Inc is a biopharmaceutical company dedicated to developing innovative therapies for patients with kidney diseases. With its lead compound vadadustat, the company is poised to make a significant impact on the treatment of anemia in CKD patients, with the potential to improve patient outcomes and quality of life.


   Company Address: 245 First Street Cambridge 2142 MA
   Company Phone Number: 871-2098   Stock Exchange / Ticker: NASDAQ AKBA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Akebia Therapeutics Inc

Akebia Therapeutics Inc Reports Impressive $56.07 Million in Revenue for Q4 2023

Akebia Therapeutics Inc, a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, has experienced a decline in its stock price over the past month. The stock has decreased by -10.91%, bringing the year-to-date performance to 15.75%. Currently, Akebia Therapeutics Inc is trading on the NASDAQ at 28.3% above its 52-week average.
In terms of financial performance, Akebia Therapeutics Inc achieved a break-even point with a moderate improvement in revenue of 1.838% to $56.07 million in the December 31, 2023 report. This represents an increase from the same financial reporting period the previous year. Comparatively, in the preceding financial reporting period, the company reported a loss of $0.08 per share, and revenue surged by 33.363% from $42.05 million.

Akebia Therapeutics Inc

Revised headline: Akebia Therapeutics Inc. Makes Strides in Enhancing Financial Performance Despite Decreased Revenue in Recent Fiscal Period



Akebia Therapeutics Inc. recently released its financial results for the fiscal time-frame ending September 30, 2023. The results indicate a notable improvement compared to the previous year, showing a reduced net deficit and a decline in inventories. While the revenue decreased during this period, there are still positive signs for the company's future. This article explores the implications of these financial results and their potential impact on Akebia Therapeutics Inc.
Improvement in Earnings
In the fiscal time-frame closing September 30, 2023, Akebia Therapeutics Inc. managed to reduce its loss per share to $-0.08, an improvement from the $-0.28 loss per share reported in the previous year. Additionally, the deficit decreased from $-0.06 per share in the preceding quarter. These improvements suggest that the company is making significant efforts to streamline its operations and enhance its financial performance.

Akebia Therapeutics Inc

Akebia Therapeutics Inc's Revenue Plummets by Over 55%: Shares Surge Despite Financial Woes


Introduction
Akebia Therapeutics Inc, a leading biopharmaceutical company, has recently encountered a significant decline in its financial performance, as indicated by its latest financial report for the second quarter ending June 30, 2023. Despite a notable decrease in revenue and earnings, the company's shares have seen substantial growth on the NASDAQ. This article aims to interpret the recent financial results of Akebia Therapeutics Inc and evaluate possible implications for the company's future.
Financial Performance and Setbacks
According to Akebia Therapeutics Inc's financial report, revenue revealed a devastating decline of -55.525% to $56.38 million in the second quarter of 2023 compared to the same period the previous year. Simultaneously, the net deficit per share increased to $-0.06 from $-0.14, signifying a worsening financial situation for the company.

Akebia Therapeutics Inc

Akebia Therapeutics Inc.'s Financial Report Reveals Disappointing Numbers with a Significant Drop in Revenue and Net Deficit

Akebia Therapeutics Inc., a renowned biotechnology company, has recently disclosed its financial report for the first quarter of 2023, which has drawn the attention of market analysts due to its disappointing numbers. The overall revenue of the company has plummeted by -34.963% compared to the corresponding reporting period in the previous year and stood at $40.13 million. The company has reported a net deficit per share of $-0.14, which is a significant drop from the net deficit of $-0.35 in the previous year.
These disappointing numbers come as a surprise to many, as the company had previously reported a loss of only $-0.04 per share in the preceding financial reporting period, indicating a significant decline in performance. Moreover, the revenue has also taken a toll, falling by -27.28% from $55.18 million in the corresponding reporting period in the previous year.
In terms of net loss, Akebia Therapeutics Inc. reported a loss of $-26.217 million in the financial interval ending on March 31, 2023. This is much better than the corresponding period in the previous year, where the company had reported a net deficit of $-62.421 million. However, this does not justify the overall disappointing numbers, and the company needs to take proactive measures to improve its financial performance.






 

Akebia Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Akebia Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Akebia Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com